Shanghai Genechem Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Private, Subsidiary
- Established
- 2013-09-22
- Employees
- 251
- Market Cap
- -
- Website
- https://www.genechem.com.cn
Clinical Trials
7
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:6
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Not Applicable
1 (14.3%)A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03130712
- Locations
- 🇨🇳
302 Military Hospital, Beijing, China
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
Phase 1
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: anti-CD19-CAR-T cells
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT03030976
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Phase 1
- Conditions
- Colorectal Cancer MetastaticCarcinoma, HepatocellularPancreatic Cancer Metastatic
- Interventions
- Drug: CAR-T cell
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02959151
- Locations
- 🇨🇳
Shanghai Tumor Hospital, Shanghai, Shanghai, China
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Phase 1
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: TAI-GPC3-CART cells
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02715362
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Phase 1
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: TAI-meso-CART
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Shanghai GeneChem Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02706782
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
- Prev
- 1
- 2
- Next
News
No news found